Bruker Expands Infection Detection Portfolio with Acquisition of Metagenomic mNGS DISQVER® Platform for Pathogenic Microorganisms in Blood
Bruker Corporation (NASDAQ:BRKR) today announced the acquisition of the DISQVER® clinical metagenomics platform from Noscendo GmbH.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260715763519/en/
View source version on businesswire.com: https://www.businesswire.com/news/home/20260715763519/en/
Trade Press & Customer Contact:
Alessandro Abramo
Director Marketing & Product Management
Bruker Microbiology & Infection Diagnostics
T: +39-348-360-9058
E: alessandro.abramo@bruker.com
Investor Contact:
Joe Kostka
Director, Investor Relations & Corporate Development
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com